Orbis Medicines’ Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection.
Cigna Ventures and Bright's majority shareholder, New Enterprise Associates, are contributing to the financing. It comes as Bright faces higher-than-expected medical costs during the pandemic.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
The Boston-based company plans to develop small-molecule therapeutics that go after historically "undruggable" targets using a process known as protein degradation.
Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.
The insurance startup led by UnitedHealthcare’s former CEO closed a $635 million funding round led by New Enterprise Associates.
In a letter addressed to Gottlieb, Warren implored him to resign from board of the Big Pharma company, writing "this kind of revolving door influence-peddling smacks of corruption."
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The announcement that the former Food and Drug Administration commissioner would join the pharma giant's board had many on social media criticizing what they saw as a revolving door between government and industry.
Gottlieb previously worked at NEA from 2007 to 2017, when he was appointed as commissioner of the FDA. He stepped down from that role in March, also returning to another previous employer, the American Enterprise Institute.
The raise comes a month after the Cambridge, Massachusetts-based firm's launch with a $20 million Series A round. Black Diamond is developing drugs that target allosteric mutant oncogenes, which it describes as an unexplored space.
With New Enterprise Associates at the helm of the round, the company is setting out to develop antibiotics for drug-resistant bacterial infections.
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.
The Manhattan Beach, California-based startup has raised $3.5 million in a seed round of funding from Green Bay Ventures, Sanofi Ventures, Flare Capital Partners and New Enterprise Associates.
Bessemer Ventures and New Enterprise Associates led Bright Health's Series A round. The company is led Bob Sheehy.
New Enterprise Associates just led a $35 million Series B round for British gene therapy startup NightstaRx, which is developing a viral vector-based therapy for inherited vision loss.
Therachon has raised significant funding to support clinical proof of its soluable form of human fibroblast growth factor receptor 3. This could treat achondroplasia, a genetic mutation that is the leading cause of dwarfism.